{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:37:20Z","timestamp":1761129440334},"reference-count":0,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Purpose: Crohn\u2019s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract. It is usually considered a contraindication to transrectal ultrasound-guided prostate biopsy (TRUSBx). The aim of this study was to investigate the safety of TRUSBx in a small cohort of patients with CD. Methods: We queried our institutional database clinical data of patients with a diagnosis of CD undergoing TRUSBx, and a retrospective prospective study of 5 patients was planned. All patients enrolled were in the remission phase of CD and asymptomatic. They received the same antibiotic prophylaxis and a povidone-iodine aqueous solution enema before the procedure. A standardized reproducible technique was used with using a ultrasound machine equipped with a 5-9 MHz multifrequency convex probe \u201cend-fire\u201d. The patients were treated under local anaesthesia, and a 14-core biopsy scheme was performed in each patient as first intention. After the procedure each patient was given a verbal numeric pain scale to evaluate tolerability of TRUSBx. Results: TRUSBx was successfully completed in all patients. The number of biopsy cores was 14 (12-16). Of the 5 biopsy procedures performed 40% revealed prostatic carcinoma (PCa) with a Gleason score 6 (3+3). No patients required catheterization or admission to the hospital for adverse events after the procedure. The most frequent adverse event was hematospermia (60%), while hematuria was present in 20% of patients and a minimal rectal bleeding in 20% of the patients. No patients reported severe or unbearable pain (score \u2265 8). Conclusions: This study suggests that CD may not be an absolute contraindication to TRUSBx for prostate cancer detection, but still requires a careful patients selection.<\/jats:p>","DOI":"10.4081\/aiua.2017.2.106","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T07:09:42Z","timestamp":1500620982000},"page":"106","source":"Crossref","is-referenced-by-count":2,"title":["Safety of transrectal ultrasound-guided prostate biopsy in patients affected by Crohn\u2019s disease"],"prefix":"10.4081","volume":"89","author":[{"given":"Lucio","family":"Dell'Atti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Benedetto","family":"Galosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2017,6,30]]},"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"http:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/viewFile\/6697\/6575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T10:43:46Z","timestamp":1500633826000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/view\/aiua.2017.2.106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,30]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2017.2.106","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}